Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy.

"Declaration of interests A.S. is a cofounder of, and has equity in, Lacerta Therapeutics. He also serves on the scientific advisory board of 4D Molecular Therapeutics. He is an inventor on several issued and filed patents on recombinant AAV vectors that have been or are being licensed to various AAV gene therapy companies. B.J.B. is an inventor of AAV-related patents that have been licensed to various AAV gene therapy companies. He is a co-founder and equity holder in Lacerta Therapeutics. D.D. is a member of the scientific advisory board for Solid Biosciences and equity holder in Solid Biosciences. He is also a member of the scientific advisory board of Sardocor Corporation. All of the other authors declare no competing interests."

"This research was supported in part by 10.13039/100014943Sarepta Therapeutics, 10.13039/100000002National Institutes of Health grant nos. R01GM-119186 (to A.S.) and R21 AR-081018 (to A.S. and D.D.), the 10.13039/100018268Children’s Miracle Network, and the 10.13039/100018043Kitzman Foundation (to A.S.)."